首页> 美国卫生研究院文献>Pharmaceutical Biology >Total flavones of Abelmoschus manihot improve diabetic nephropathy by inhibiting the iRhom2/TACE signalling pathway activity in rats
【2h】

Total flavones of Abelmoschus manihot improve diabetic nephropathy by inhibiting the iRhom2/TACE signalling pathway activity in rats

机译:黄bel总黄酮通过抑制大鼠iRhom2 / TACE信号通路的活性改善糖尿病性肾病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Context: Total flavones extracted from Abelmoschus manihot L. (Malvaceae) medic (TFA) have been proven clinically effective at improving renal inflammation and glomerular injury in chronic kidney disease (CKD).>Objective: This study evaluated the function of TFA as an inhibitor of iRhom2/TACE (tumour necrosis factor-α converting enzyme) signalling and investigated its anti-DN (diabetic nephropathy) effects in a DN rat model.>Materials and methods:In vitro, cells were treated with 200 μg/mL advanced glycation end products (AGEs), and then co-cultured with 20 μg/mL TFA for 24 h. Real time PCR, western blotting and co-immunoprecipitation assays were performed. In vivo, DN was induced in 8 week old male Sprague-Dawley rats via unilateral nephrectomy and intraperitoneal injection of streptozotocin, then TFA were administered to rats by gavage for 12 weeks at three different doses (300, 135 and 75 mg/kg/d). 4-Phenylbutanoic acid (2.5 mg/kg/d) was used as a positive control.>Results: IC50 of TFA is 35.6 μM in HK2 and 39.6 μM in HRMC. TFA treatment (20 μM) inhibited the activation of iRhom2/TACE signalling in cultured cells induced by AGEs. LD50>26 g/kg and ED50=67 mg/kg of TFA in rat by gavage, TFA dose-dependently downregulated the expression of proinflammatory cytokines and exerted anti-inflammatory effects significantly though inhibiting the activation of iRhom2/TACE signalling.>Discussion and conclusions: Our results show that TFA could dose-dependently ameliorate renal inflammation by inhibiting the activation of iRhom2/TACE signalling and attenuating ER stress. These results suggest that TFA has potential therapeutic value for the treatment of DN in humans.
机译:>背景:已证明从苦艾科(Abelmoschus manihot L.)(TFA)提取的总黄酮具有改善慢性肾脏病(CKD)的肾脏炎症和肾小球损伤的临床效果。>目的:< / strong>这项研究评估了TFA作为iRhom2 / TACE(肿瘤坏死因子-α转换酶)信号抑制剂的功能,并研究了其在DN大鼠模型中的抗DN(糖尿病肾病)作用。>材料和方法::在体外,将细胞用200μg/ mL的高级糖基化终产物(AGEs)处理,然后与20μμg/ mL的TFA共培养24h。进行实时PCR,蛋白质印迹和免疫共沉淀试验。在体内,通过单侧肾切除术和腹膜内注射链脲佐菌素在8周大的雄性Sprague-Dawley大鼠中诱导DN,然后以三种不同剂量(300、135和75μmg/ kg / d)灌胃对大鼠进行TFA给药12周)。以4-苯基丁酸(2.5μmg/ kg / d)为阳性对照。>结果: TFA在HK2中的IC50为35.6μM,在HRMC中为39.6μM。 TFA处理(20μm)可抑制AGEs诱导的培养细胞中iRhom2 / TACE信号的激活。通过灌胃法对大鼠的TFA LD50>26μg/ kg和ED50 =67μmg/ kg,TFA剂量依赖性地下调促炎细胞因子的表达,并通过抑制iRhom2 / TACE信号的激活显着发挥抗炎作用。>讨论与结论:我们的结果表明,TFA可以通过抑制iRhom2 / TACE信号的激活和减轻ER应激来剂量依赖性地改善肾脏炎症。这些结果表明,TFA对于人类DN的治疗具有潜在的治疗价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号